How to In-License Biotech Assets from China: A Strategic Playbook
A practical guide for Western BD executives on scouting, evaluating, and acquiring Chinese biotech innovation — from first contact to deal close.
Why In-License from China Now?
The global pharmaceutical innovation map has been fundamentally redrawn. For three decades, China was the world's contract manufacturer — the place where active pharmaceutical ingredients were made cheaply and in volume. Today, that story is obsolete. China has undergone a structural innovation reversal, transitioning from a generic copier into a world-class originator of novel therapeutic assets. Its biotech ecosystem — anchored in Shanghai, Beijing, Suzhou, and Shenzhen — now rivals Boston and London in the density of clinical-stage innovation.
The numbers tell the story plainly. In 2024 and 2025 combined, Chinese biotech companies executed more than $30 billion in outbound licensing deals with Western pharmaceutical companies. This is not speculative pipeline trading — these are validated, often late-stage assets licensed to Pfizer, AstraZeneca, GSK, Roche, AbbVie, and Regeneron. We track the full picture in our China biotech outbound licensing tracker.
The most dramatic indicator of China's innovation leadership is its dominance in Antibody-Drug Conjugate chemistry. Chinese companies now account for approximately 90% of all new ADC licensing activity globally — a molecule class that has produced some of the most valuable oncology deals of the last five years. Kelun-Biotech, MediLink Therapeutics, and Duality Biotherapeutics have become household names in oncology business development.
For Western BD executives, the urgency is real: the window for licensing premium Chinese assets at reasonable valuations is closing. Early movers like AstraZeneca, which acquired rights to ivonescimab and multiple ADC platforms before valuations normalized, gained structural competitive advantages. As NMPA data becomes increasingly FDA-accepted and deal precedents pile up, Chinese licensors are becoming far more sophisticated in their negotiating positions. The "China discount" on upfront payments — historically 30-50% below equivalent Western assets — is narrowing with each successive headline deal.
$30B+ in outbound China biotech licensing in 2024-2025
Where to Find Chinese Biotech Assets
Sourcing Chinese biotech assets requires a multi-channel approach that combines global conference presence, database intelligence, and in-country relationship networks. The best deals are almost never found through a cold database search alone — they come from trusted local intermediaries and established conference relationships.
Conferences: Where Deals Begin
J.P. Morgan Healthcare Conference
San Francisco, January. The global biotech dealmaking epicenter. Chinese companies now send large delegations — often their most senior BD and C-suite executives — specifically to initiate Western licensing conversations.
BIO International Convention
June, rotating US cities. The largest biotech partnering event globally. The BIO One-on-One Partnering system enables targeted meetings with Chinese companies across all therapeutic areas.
ChinaBio Partnering Forum
Shanghai, typically Q2/Q3. The most concentrated event specifically for China cross-border licensing. Attendance signals serious licensing intent from Chinese companies.
CPHI China
Shanghai, June. Pharmaceutical manufacturing and supply chain focus. Critical for identifying CMC capabilities, CDMO relationships, and manufacturing transferability of Chinese assets.
Databases and Intelligence Sources
Commercial databases are essential for systematic pipeline scouting. Cortellis Drug Intelligence (Clarivate) provides the most comprehensive tracking of Chinese clinical-stage assets, deal transactions, and patent activity. Evaluate Pharma is indispensable for commercial forecasting and valuation benchmarking. For IP-level intelligence, the CNIPA (China National Intellectual Property Administration) patent database provides direct access to Chinese filing activity — often revealing innovation months before it appears in Western databases.
China's National Key R&D Program (NKP) is an underutilized intelligence source for Western BD teams. The NKP tracks government-funded innovation across Chinese universities and institutes — often the earliest signal of a breakthrough technology before it has been spun out into a commercial entity. Monitoring NKP grants in oncology, immunology, and metabolic disease gives a 2-3 year lead time on commercially interesting programs.
Local Networks and In-Country Presence
No database replaces the value of an in-country BD network. Hong Kong functions as the strategic gateway hub between mainland China and the Western financial and legal ecosystem. Most major Chinese biotech companies have Hong Kong offices, and many use Hong Kong holding structures for their licensing arrangements. Being present in Hong Kong — or having trusted partners there — dramatically accelerates deal access.
In mainland China, Shanghai (Zhangjiang Pharma Valley) and Beijing (Zhongguancun Life Sciences Park) are the primary innovation hubs. Local BD representatives with deep relationships in these ecosystems can access pre-publication pipeline data, introductions to company founders, and early-stage partnering opportunities that never appear at international conferences. Vision Lifesciences maintains proprietary scouting networks in Shanghai, Beijing, and Hong Kong — enabling access to assets well before they enter formal out-licensing processes.
Social channels matter more than Western BD executives typically expect. WeChat biotech communities and Chinese biotech investor networks (including family offices and healthcare-focused VCs in the Cayman/BVI structure space) are active deal origination channels. A credible WeChat presence within the Chinese biotech BD community signals serious engagement and often opens doors that formal outreach cannot.
Therapeutic Areas with the Strongest China Pipelines
Not all Chinese biotech innovation is created equal. Five therapeutic areas stand out as exceptional sources of licensable, globally competitive assets — each with distinct scientific advantages rooted in China's unique patient population, manufacturing capabilities, or research focus. For a comprehensive analysis of available assets, see our China biotech licensing opportunities report.
ADC (Antibody-Drug Conjugates)
China leads globally. ~90% of new ADC licensing activity originates from Chinese companies. Kelun-Biotech, MediLink, and Duality Bio have set the benchmark for next-generation linker-payload chemistry and dual-payload ADC design.
Bispecific Antibodies
PD-1/VEGF bispecifics are the defining innovation — ivonescimab (AstraZeneca / Summit Therapeutics) is the lead example. A second wave of PD-L1/VEGF, PD-1/HER2, and EGFR combinations is in active development across dozens of Chinese companies.
GLP-1 & Metabolic
Oral GLP-1 small molecules, triple agonists (GLP-1/GIP/GCG), and extended half-life peptide variants. China's massive T2D patient population drives unmatched clinical enrollment speed and pharmacokinetic optimization capabilities.
CAR-T / Cell Therapy
SLE CAR-T therapy is a world-leading area, with Chinese clinical data ahead of any Western program. Solid tumor CAR-T programs are earlier but represent a significant pipeline. Autoimmune CAR-T is China's emerging breakthrough area.
Oncology (NSCLC, HCC, Gastric)
China's massive patient population in NSCLC, hepatocellular carcinoma, and gastric cancer provides unmatched clinical trial depth. Chinese companies have first-mover data in multiple subsets that Western companies lack access to.
The ADC Leadership Gap
Due Diligence Framework: The Three Pillars
Standard pharmaceutical due diligence frameworks, designed for Western asset evaluation, are insufficient for Chinese biotech assets. The risks are different in character, distribution, and detectability. At Vision Lifesciences, we apply a "Three Pillars" due diligence framework specifically designed for the China cross-border context.
Pillar 1 — Data Integrity
Clinical data generated in China must be verified for cross-border regulatory compatibility before any licensing investment decision. The key requirements are:
- ICH E6(R3) GCP compliance: Confirm that clinical operations followed the updated Good Clinical Practice standards aligned with FDA and EMA expectations.
- Grade-3A NMPA-certified hospitals: Clinical sites must be certified at the highest tier of Chinese hospital classification to be accepted in global submissions.
- FDA cross-compatibility audit: Review source documents, data management systems, and statistical analysis plans for FDA IND compatibility. Gaps can be remediated but cost time and capital.
- HGRAC compliance: Clinical data involving Chinese patients is subject to the Human Genetic Resources Administration of China. Export of such data requires a formal security assessment. Deals without clear HGRAC compliance have been blocked post-signing.
Pillar 2 — CMC & Manufacturing
Chemistry, Manufacturing, and Controls (CMC) is where Chinese assets most frequently face Western market entry barriers. The core questions are:
- Technology transfer feasibility: Can the manufacturing process be transferred to a Western-compliant CDMO without loss of biological equivalence? Some Chinese biotech processes are highly proprietary and transfer-resistant.
- BIOSECURE Act CDMO check: Is the Chinese licensor's current CMO on the BIOSECURE Act restricted entities list (WuXi AppTec, BGI Genomics, et al.)? If yes, a tech transfer to a non-restricted CDMO is a commercial precondition.
- Analytical method validation: Confirm that analytical methods meet FDA/EMA submission standards. Chinese internal methods often require re-validation to ICH Q2 standards for Western submissions.
- Commercial-scale scalability: Assess whether the current manufacturing process can be scaled to commercial volumes (10,000L+ bioreactors for biologics) without material process changes that would require additional regulatory bridging.
Pillar 3 — IP & Freedom to Operate
Intellectual property risk in Chinese assets has a unique profile that differs substantially from Western IP due diligence. Key areas of scrutiny:
- CNIPA patent landscape: Conduct a comprehensive analysis of the Chinese patent database for the target compound, combination, and method-of-use claims. The CNIPA filing system has material differences from USPTO that require specialist analysis.
- "Improvement patents" risk: A critical China-specific hazard. Some Chinese originators file continuation and improvement patents that could restrict the licensee's ability to optimize or formulate the asset in Western markets. These must be identified and addressed in the license agreement.
- Global FTO from day one: Freedom-to-Operate analysis should cover US, EU, and Japan from the outset — not just China. Initiating FTO analysis after term sheet signing is a common mistake that delays deal close by 2-4 months.
- Technology transfer export controls: China's export control laws (implemented from 2020 onward) may restrict transfer of certain dual-use biotechnologies. Legal counsel with specific China export control expertise is required to assess this risk for each asset class.
Deal Structuring for China In-Licensing
The deal architecture for China-origin in-licensing has evolved significantly as both sides have become more sophisticated. The era of simple territory licenses with flat milestones is giving way to complex, multi-layered structures that balance risk distribution, data-sharing obligations, and manufacturing strategy. For a full clause-by-clause guide, see our cross-border licensing term sheet guide.
Territory Split: The Greater China Model
The dominant deal structure in 2026: the Chinese licensor retains Greater China rights (mainland, Hong Kong, Macau, and Taiwan) and licenses Rest of World (ROW) to the Western partner. This model allows the originator to manage the NMPA regulatory process locally, handle NRDL negotiations, and run its own commercial operation in China — while the licensee gains access to the high-value FDA/EMA regulatory pathways. Used in approximately 70% of current cross-border China deals.
Financial Structure: Low Upfront, Milestone-Heavy
Typical upfront payments for Chinese Phase I/II assets range from $30M to $80M — substantially below equivalent Western assets. The economic center of gravity sits in the milestone stack: IND filing ($10-25M), Phase 2 initiation ($25-75M), NDA filing ($100-250M), FDA approval ($200-500M), and tiered commercial milestones. Total deal values of $500M to $2B+ are achievable for best-in-class assets even with modest upfronts. Royalty rates for innovative Chinese assets run 8-15% of net sales for ROW rights.
The "NewCo" Joint Vehicle Model
An emerging and increasingly popular structure involves creating a joint venture NewCo to hold global rights to the asset. Both the Chinese licensor and the Western licensee take equity positions in the NewCo, which is typically incorporated in the Cayman Islands or Delaware. The NewCo structure aligns incentives, simplifies foreign exchange flows, enables co-investment by third-party capital, and provides a cleaner path to IPO or acquisition. AstraZeneca's approach to several Chinese partnering transactions has popularized this model.
Data Sharing and Manufacturing Rights
Modern China in-licensing term sheets explicitly address two critical operational matters: data sharing and manufacturing control. Data sharing clauses govern how Chinese Phase I/II clinical data can be used by the Western partner for FDA IND filings — including which data can be cross-referenced, in what format, and subject to what HGRAC restrictions. Manufacturing rights clauses define who controls the CMC process, who leads technology transfer to a Western-compliant CDMO, and at whose cost — a material commercial consideration when tech transfer to non-restricted CDMOs can cost $5-25M.
Foreign Exchange Controls
NMPA Data to FDA Acceptance: Regulatory Pathways
The most important regulatory question in any China in-licensing deal is simple: can the Chinese clinical data support US and European regulatory submissions? The answer is increasingly "yes" — but only with deliberate design from the outset. See our detailed guides on the NMPA drug approval process and China clinical trial advantages for global pharma for full regulatory context.
Multi-Regional Clinical Trial (MRCT) Design
The gold standard for China-origin assets targeting global approval is MRCT design from Phase I or Phase II onward. Including Chinese clinical sites within a global trial framework from the start means that the resulting data package supports simultaneous NDA submissions to the FDA, EMA, and NMPA. The NMPA's adoption of ICH E17 guidelines for MRCT design has made this approach increasingly feasible. Western in-licensees who receive Chinese assets mid-development can sometimes retrospectively integrate Chinese data into global dossiers — but this requires careful regulatory alignment and is significantly more complex than prospective MRCT design.
Bridging Study Model
For assets where MRCT design was not implemented from the start, the bridging study model is the most common FDA pathway. Chinese Phase I pharmacokinetic and safety data supports a US IND, enabling the licensee to initiate a US/global Phase II or Phase III without repeating full Phase I in a Western population. The FDA's acceptance of this approach varies by modality — biologics with well-characterized PK/PD profiles are more straightforward than novel small molecules. Pre-IND meetings with FDA, initiated before the licensing deal closes, are essential to validate the bridging strategy early.
FDA 505(b)(2) Pathway
For small molecule assets with substantial Chinese Phase I and Phase II data, the FDA's 505(b)(2) pathway allows an NDA to rely on published literature and existing safety data — including data from Chinese regulatory submissions — without repeating all clinical work. This pathway is particularly useful for assets that have already received NMPA conditional approval, as the Chinese NDA package can form a core part of the 505(b)(2) submission. The pathway is not available for biological products (which follow the 351(k) biosimilar or 351(a) BLA routes).
Pre-IND Meeting Strategy
The single most important regulatory action Western in-licensees should take is requesting an FDA pre-IND meeting before the licensing transaction closes — or at minimum before the term sheet is signed. This meeting establishes FDA's position on the Chinese data package, the bridging study design, and any manufacturing concerns. Using the pre-IND meeting outputs as part of deal due diligence reduces post-signing regulatory risk materially and can prevent scenarios where a multi-hundred-million-dollar upfront payment is followed by an unexpected FDA rejection of the data package.
BIOSECURE Act Compliance for In-Licensing
The BIOSECURE Act — signed into US law in late 2025 — is the most significant piece of US legislation affecting cross-border biopharma since FDAMA. For Western companies in-licensing Chinese biotech assets, understanding what the BIOSECURE Act does — and critically, what it does not — restrict is essential. We analyze the full implications in our dedicated BIOSECURE Act pharmaceutical impact guide.
What BIOSECURE Restricts
- CDMO/CMO manufacturing services from five designated "biotechnology companies of concern": WuXi AppTec, WuXi Biologics, BGI Genomics, MGI Tech, and Complete Genomics
- Use of sequencing services from BGI-linked entities by US government contractors and federal healthcare recipients
- Direct manufacturing contracts with restricted entities by companies receiving US federal funding
What BIOSECURE Does NOT Restrict
- In-licensing transactions and IP transfers from Chinese biotech companies
- Use of Chinese clinical data in FDA submissions
- CRO partnerships for clinical operations, data management, and biostatistics
- Equity investments in Chinese biotech companies
- Collaborations with Chinese CDMOs not on the restricted entities list
The practical BIOSECURE compliance requirement for in-licensing deals is a CDMO audit at due diligence. If the Chinese licensor's current manufacturing partner is WuXi Biologics or another restricted entity, the deal should include an explicit tech transfer obligation and timeline as a closing condition or post-closing covenant. The cost and timeline of tech transfer to non-restricted CDMOs — Samsung Biologics (Korea), Lonza (Switzerland), Fujifilm Diosynth Biotechnologies (US/Japan), or Wuxi STA alternatives — should be modeled into the deal economics before term sheet signing.
BIOSECURE Is a Manufacturing Question, Not a Licensing Question
How Vision Lifesciences Supports Cross-Border Scouting
Vision Lifesciences operates at the intersection of Chinese biotech innovation and Western pharmaceutical business development. Our in-licensing advisory practice is built around four core capabilities that address the specific challenges of China cross-border asset acquisition.
Proprietary Pipeline Scouting
Our Hong Kong and Shanghai offices provide access to pre-publication Chinese pipeline data and early-stage partnering opportunities that are invisible to international BD teams relying solely on conference attendance and commercial databases. We have established relationships with founders, Chief Scientific Officers, and BD leads at over 200 Chinese biotech companies across ADC, bispecific, GLP-1, and cell therapy focus areas.
Technical Due Diligence
We perform the full Three Pillars due diligence framework: data integrity audits against ICH E6(R3) and HGRAC requirements, CMC technology transfer assessments, BIOSECURE CDMO checks, and global FTO analysis including CNIPA patent landscape review. Our due diligence reports are structured for internal investment committee presentations and external legal review.
Deal Structuring & Term Sheet Negotiation
We support term sheet construction, milestone schedule optimization, royalty benchmarking, territory split structuring, and data sharing clause design. Our team has benchmarked hundreds of cross-border China licensing transactions and brings negotiation experience from both sides of the table — as advisors to both Western licensees and Chinese licensors.
Regulatory Strategy
We prepare NMPA data strategy assessments for FDA pre-IND meeting submissions, advise on MRCT design and bridging study feasibility, and support FDA pre-IND meeting preparation. Our regulatory advisory work typically begins six to twelve months before a deal closes to ensure that regulatory risk is fully quantified before capital is committed.
Frequently Asked Questions
What does in-licensing from China mean?
In-licensing from China means acquiring the rights to a Chinese biotech company's drug asset — typically for development and commercialization outside China. The Chinese company (licensor) retains its domestic rights while the Western partner (licensee) gains the rights to develop, manufacture, and sell the drug in specified territories such as the US, EU, and Japan.
What therapeutic areas are Chinese biotechs strongest in?
Chinese biotechs are globally dominant in Antibody-Drug Conjugates (ADCs), accounting for roughly 90% of new global ADC licensing activity. They are also highly competitive in bispecific antibodies (particularly PD-1/VEGF combinations), GLP-1 and metabolic disease assets, CAR-T cell therapies (especially in autoimmune SLE applications), and oncology broadly — particularly NSCLC, HCC, and gastric cancer.
Does the BIOSECURE Act prevent in-licensing from China?
No. The BIOSECURE Act restricts the use of specific designated Chinese CDMO/CMO companies for manufacturing services — primarily WuXi AppTec, BGI Genomics, and three other named entities. It does NOT restrict IP licensing deals, clinical data transfers, or most CRO partnerships. Western companies can freely in-license Chinese biotech assets, provided that downstream manufacturing does not use restricted CDMOs.
How much does it cost to in-license a China biotech asset?
Typical upfront payments for in-licensing Chinese biotech assets range from $20M to $100M, with milestone-heavy deal structures making up the bulk of total deal value ($500M to $5B+). Chinese assets are generally available at 30-50% lower upfronts than equivalent US or European assets at the same development stage — reflecting a "China discount" that is narrowing as data quality and deal precedents improve.
What is a "Greater China rights" deal structure?
In a Greater China rights deal, the Chinese licensor retains commercial and development rights in Greater China (mainland China, Hong Kong, Macau, and Taiwan), while the licensee acquires global ex-China rights (Rest of World, often including the US, EU, Japan, and other markets). This is the most common structure in cross-border China biotech deals, used in approximately 70% of transactions.
How do I verify Chinese clinical data quality?
Verifying Chinese clinical data quality requires a multi-step approach: confirm that clinical sites are Grade-3A NMPA-certified hospitals; conduct a GCP (Good Clinical Practice) audit aligned with ICH E6(R3) standards; check for HGRAC compliance for human genetic resource data exports; cross-reference source documents against submitted data packages; and assess whether the data package can support an FDA IND or pre-IND meeting without additional bridging studies.
Find your next China biotech asset with Vision Lifesciences
Our cross-border BD team combines in-country scouting presence in Shanghai and Hong Kong with deep technical due diligence and deal structuring expertise. Let us identify, evaluate, and help you close the Chinese biotech asset that fits your pipeline strategy.
Need expert guidance on your next deal?
Our team of life sciences advisors can help you navigate complex transactions, from early-stage licensing to full M&A.
Related Strategic Insights
Cross-Border Licensing Term Sheet Guide: Structuri...
A practical, clause-by-clause walkthrough of pharmaceutical licensing term sheets—with real-world benchmarks and China-s...
Pharma Due Diligence Checklist: The Complete Guide...
A comprehensive, practical checklist covering scientific, IP, regulatory, commercial, financial, and manufacturing due d...
In-Licensing vs Out-Licensing: The Complete Guide
A strategic framework for cross-border asset acquisition, monetization, and partnership structuring.